Braftovi and Junel Fe 1.5/30

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Encorafenib may reduce the blood levels and effects of ethinyl estradiol, which may make it less reliable as a form of birth control. Alternative, non-hormonal methods of birth control should be used during treatment with encorafenib to avoid unintended pregnancy. This is particularly important because encorafenib may cause harm in the unborn child. Talk to your gynecologist or other healthcare professional for help in selecting an effective method of birth control that is best for you. If you take hormone replacement for menopause, you should contact your doctor if you experience increased frequency or worsening of your symptoms such as hot flashes, vaginal dryness, or abnormal bleeding. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with encorafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The proposed mechanism is induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones. Although specific pharmacokinetic studies have not been conducted, encorafenib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.

MANAGEMENT: Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with encorafenib. Because encorafenib can cause fetal harm, it is particularly important that patients not become pregnant during treatment. Therefore, females of reproductive potential should use an effective, nonhormonal method of contraception during treatment and for 2 weeks after the final dose of encorafenib. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.

Braftovi

Generic Name: encorafenib

Brand name: Braftovi

Synonyms: n.a.

What is Braftovi?

Junel Fe 1.5/30

Generic Name: ethinyl estradiol / norethindrone

Brand name: Blisovi 24 Fe, Blisovi Fe 15/30, Blisovi Fe 1/20, Estrostep Fe, Gildess 24 Fe, Gildess Fe 15/30, Gildess Fe 1/20, Junel Fe 15/30, Junel Fe 1/20, Junel Fe 24, Larin 24 Fe, Larin Fe 15/30, Larin Fe 1/20, Lo Loestrin Fe, Loestrin 24 Fe, Loestrin Fe 15/30, Loestrin Fe 1/20, Lomedia 24 Fe, Microgestin 24 Fe, Microgestin Fe 15/30, Microgestin Fe 1/20, Tarina Fe 1/20, Taytulla, Tilia Fe, Tri-Legest Fe, Blisovi 24 Fe, Femcon Fe, Kaitlib FE, Lo Minastrin Fe, Microgestin 24 Fe, Norinyl 1+35, Ortho-Novum 7/7/7, Tri-Norinyl, Zenchent, femhrt 05 mg/25 mcg, Fyavolv, Jevantique Lo, Jinteli, Femcon Fe, Generess FE, Loestrin 1/20, Ovcon 35, Brevicon

Synonyms: n.a.

What is Junel Fe 1.5/30?